首页 > 最新文献

Frontiers in clinical diabetes and healthcare最新文献

英文 中文
Adherence to diabetic self-care management and associated factors among type 2 diabetic patients in North Shewa Zone public hospitals in Amhara Region, Ethiopia. 埃塞俄比亚阿姆哈拉地区北谢瓦区公立医院2型糖尿病患者对糖尿病自我保健管理的依从性及其相关因素
Pub Date : 2025-05-09 eCollection Date: 2025-01-01 DOI: 10.3389/fcdhc.2025.1560907
Agizew Endale, Fitsum Hundessa, Eyasu Tamru, Fetene Nigussie, Minyahl Hailu

Introduction: Adherence to diabetes self-care management is a lifestyle modification for people with diabetes.

Objective: To assess adherence to diabetic self-care management and associated factors among type 2 diabetic patients in North Shewa Zone public hospitals, Ethiopia, 2023.

Methods: The study employed a concurrent mixed-methods approach among 600 type 2 diabetic patients in North Shewa Zone public hospitals in Amhara, Ethiopia. The study was conducted from May 5 to May 20, 2023. The quantitative data were collected by using a semi-structured interview-administered questionnaire and chart review. Logistic regression was employed, and a p-value < 0.05 was considered statistically significant. Qualitative data were collected by in-depth interviews, and audio recordings were first transcribed verbatim and then translated to the English language by the first author and analyzed manually using a thematic approach.

Result: Out of the total 600 type 2 diabetic patients, 262 (43.7%) with 95% CI: 40-47.8% of the study participants had good adherence to diabetes self-care practices. The multivariable analysis indicated that type 2 diabetic patients who lived in urban areas [AOR: 5.4, 95% CI: (1.05-8.7)] were 5.4 times more likely to have good diabetic self-care practice than those rural residents. Those who had a high school level of education [AOR: 2.9, 95% CI: (1.3-6.6)] were 2.9 times more likely to have good self-care practice, and those with college and above [AOR: 5, 95% CI (2-12):] were five times more likely to have good self-care practice. Regarding occupation, unemployed people were 66% less likely to have good self-care practices than employed people. Those who had no availability of healthcare services [AOR: 0.19, 95% CI: (0.09-0.37)] were less likely by 81% to have good self-care practice than those who had availability of healthcare services. These are significantly associated with diabetic self-care practice. The qualitative component clarified six themes: lack of education and awareness, financial affordability, accessibility, lack of family support, and having diabetic-related complications were identified as barriers.

Conclusion: This study indicated that adherence of patients with type 2 diabetes to the recommended self-care practices was considerably poor. Different factors included the respondents who had a high school level or higher level of education and those who lived in urban areas. This was supported by the results from the qualitative part and thus the endorsement to strengthen diabetes health education to patients and their families. So, diabetic patients require an integrated approach through treatment as well as health education, which will increase the health and well-being of the patient.

导言:坚持糖尿病自我保健管理是糖尿病患者生活方式的一种改变。目的:评估埃塞俄比亚北谢瓦区公立医院2型糖尿病患者糖尿病自我保健管理的依从性及其相关因素。方法:对埃塞俄比亚阿姆哈拉北谢瓦区公立医院的600名2型糖尿病患者采用并行混合方法进行研究。该研究于2023年5月5日至5月20日进行。定量数据的收集采用半结构化的访谈问卷和图表回顾。采用Logistic回归,p值< 0.05为差异有统计学意义。通过深度访谈收集定性数据,录音首先逐字转录,然后由第一作者翻译成英语,并使用主题方法进行人工分析。结果:在总共600名2型糖尿病患者中,262名(43.7%)(95% CI: 40-47.8%)的研究参与者良好地遵守了糖尿病自我保健实践。多变量分析显示,生活在城市地区的2型糖尿病患者[AOR: 5.4, 95% CI:(1.05-8.7)]良好的糖尿病自我保健行为的可能性是农村居民的5.4倍。那些具有高中教育水平的人[AOR: 2.9, 95% CI:(1.3-6.6)]具有良好自我保健行为的可能性是2.9倍,而那些具有大学及以上学历的人[AOR: 5, 95% CI(2-12):]具有良好自我保健行为的可能性是5倍。就职业而言,失业人员拥有良好自我保健习惯的可能性比就业人员低66%。那些没有医疗保健服务的人[AOR: 0.19, 95% CI:(0.09-0.37)]有良好自我保健习惯的可能性比有医疗保健服务的人低81%。这些与糖尿病患者的自我保健实践显著相关。定性部分明确了六个主题:缺乏教育和意识、经济负担能力、可及性、缺乏家庭支持和患有糖尿病相关并发症被确定为障碍。结论:本研究表明,2型糖尿病患者对推荐的自我保健做法的依从性相当差。不同的因素包括受教育程度为高中或高中以上的受访者和居住在城市地区的受访者。质性部分的结果支持了这一结论,从而为加强对患者及其家属的糖尿病健康教育提供了支持。因此,糖尿病患者需要综合治疗和健康教育,这将增加患者的健康和福祉。
{"title":"Adherence to diabetic self-care management and associated factors among type 2 diabetic patients in North Shewa Zone public hospitals in Amhara Region, Ethiopia.","authors":"Agizew Endale, Fitsum Hundessa, Eyasu Tamru, Fetene Nigussie, Minyahl Hailu","doi":"10.3389/fcdhc.2025.1560907","DOIUrl":"10.3389/fcdhc.2025.1560907","url":null,"abstract":"<p><strong>Introduction: </strong>Adherence to diabetes self-care management is a lifestyle modification for people with diabetes.</p><p><strong>Objective: </strong>To assess adherence to diabetic self-care management and associated factors among type 2 diabetic patients in North Shewa Zone public hospitals, Ethiopia, 2023.</p><p><strong>Methods: </strong>The study employed a concurrent mixed-methods approach among 600 type 2 diabetic patients in North Shewa Zone public hospitals in Amhara, Ethiopia. The study was conducted from May 5 to May 20, 2023. The quantitative data were collected by using a semi-structured interview-administered questionnaire and chart review. Logistic regression was employed, and a p-value < 0.05 was considered statistically significant. Qualitative data were collected by in-depth interviews, and audio recordings were first transcribed verbatim and then translated to the English language by the first author and analyzed manually using a thematic approach.</p><p><strong>Result: </strong>Out of the total 600 type 2 diabetic patients, 262 (43.7%) with 95% CI: 40-47.8% of the study participants had good adherence to diabetes self-care practices. The multivariable analysis indicated that type 2 diabetic patients who lived in urban areas [AOR: 5.4, 95% CI: (1.05-8.7)] were 5.4 times more likely to have good diabetic self-care practice than those rural residents. Those who had a high school level of education [AOR: 2.9, 95% CI: (1.3-6.6)] were 2.9 times more likely to have good self-care practice, and those with college and above [AOR: 5, 95% CI (2-12):] were five times more likely to have good self-care practice. Regarding occupation, unemployed people were 66% less likely to have good self-care practices than employed people. Those who had no availability of healthcare services [AOR: 0.19, 95% CI: (0.09-0.37)] were less likely by 81% to have good self-care practice than those who had availability of healthcare services. These are significantly associated with diabetic self-care practice. The qualitative component clarified six themes: lack of education and awareness, financial affordability, accessibility, lack of family support, and having diabetic-related complications were identified as barriers.</p><p><strong>Conclusion: </strong>This study indicated that adherence of patients with type 2 diabetes to the recommended self-care practices was considerably poor. Different factors included the respondents who had a high school level or higher level of education and those who lived in urban areas. This was supported by the results from the qualitative part and thus the endorsement to strengthen diabetes health education to patients and their families. So, diabetic patients require an integrated approach through treatment as well as health education, which will increase the health and well-being of the patient.</p>","PeriodicalId":73075,"journal":{"name":"Frontiers in clinical diabetes and healthcare","volume":"6 ","pages":"1560907"},"PeriodicalIF":0.0,"publicationDate":"2025-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12098080/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144144600","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Editorial: Ethnic inequalities in diabetes care and outcomes. 社论:糖尿病治疗和结果中的种族不平等。
Pub Date : 2025-05-09 eCollection Date: 2025-01-01 DOI: 10.3389/fcdhc.2025.1595078
Suma Uday
{"title":"Editorial: Ethnic inequalities in diabetes care and outcomes.","authors":"Suma Uday","doi":"10.3389/fcdhc.2025.1595078","DOIUrl":"https://doi.org/10.3389/fcdhc.2025.1595078","url":null,"abstract":"","PeriodicalId":73075,"journal":{"name":"Frontiers in clinical diabetes and healthcare","volume":"6 ","pages":"1595078"},"PeriodicalIF":0.0,"publicationDate":"2025-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12098022/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144144605","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prevalence of nephropathy among patients with diabetes mellitus in Africa: a systematic review and meta-analysis. 非洲糖尿病患者肾病患病率:系统回顾和荟萃分析
Pub Date : 2025-04-25 eCollection Date: 2025-01-01 DOI: 10.3389/fcdhc.2025.1551088
Grace I Adebayo-Gege, Peter Ifeoluwa Adegbola, Lawrence Dayo Adedayo, Adegboyega Moses Oyefabi, Ifeoluwa Temitayo Oyeyemi, Odeniran Olubukola, Adewale Adegboyega Oke, Oluchukwu Perpetual Okeke, Olunike Rebecca Abodunrin, Folahanmi Tomiwa Akinsolu, Olajide Odunayo Sobande

Background: Diabetic nephropathy (DN) is one of the most frequent microvascular consequences of diabetes, accounting for a significant portion of morbidity and mortality in diabetic patients in Africa. This study aims to report on the prevalence of nephropathy among patients with diabetes mellitus patients in Africa and the risk factors.

Methods: This systematic review was reported using Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) standards, and the protocol was pre-registered in PROSPERO with the registration number CRD42024587467. The search was conducted across databases such as PubMed, Google Scholar, CINAHL and Scopus to retrieve studies published between January 2000 and August 2024. All statistical analyses were conducted using R software (version 4.4.2). The pooled prevalence of nephropathy in patients with diabetes was calculated with a 95% confidence interval (CI).

Results: Thirty-four (34) articles met the inclusion criteria. Only 28 studies were incorporated into the meta-analysis to determine the pooled prevalence of nephropathy among diabetes patients. The findings indicated a pooled prevalence of 21% (95%, CI: 16-28) of nephropathy among diabetes patients. Among type 1 and type 2 diabetes patients, the pooled prevalence of nephropathy is 46% (95%, CI: 18-77, I² = 98%) and 20% (95% CI: 14-27, I² = 98%), respectively. Weighted prevalence of 47%, 31%, 33% and 11% were reported in North Africa, Central Africa, South Africa and West Africa respectively. The result also showed that diabetes patients with hypertension are more than three times at risk of developing nephropathy compared to those without hypertension OR:3.46 (95% CI: 2.61-4.59).

Conclusion: The current study showed the prevalence of nephropathy with a significant association with hypertension among diabetic mellitus patients. Higher prevalence in North Africa is likely due to Western cultural impacts on dietary consumption.

Systematic review registration: https://www.crd.york.ac.uk/prospero/, identifier CRD42024587467.

背景:糖尿病肾病(DN)是糖尿病最常见的微血管后果之一,占非洲糖尿病患者发病率和死亡率的很大一部分。本研究旨在报道非洲糖尿病患者肾病患病率及危险因素。方法:本系统评价采用系统评价和荟萃分析首选报告项目(PRISMA)标准进行报告,该方案在PROSPERO预注册,注册号为CRD42024587467。检索是在PubMed、b谷歌Scholar、CINAHL和Scopus等数据库中进行的,检索2000年1月至2024年8月之间发表的研究。所有统计分析均使用R软件(4.4.2版)进行。以95%可信区间(CI)计算糖尿病患者肾病的总患病率。结果:34篇文章符合纳入标准。只有28项研究被纳入荟萃分析,以确定糖尿病患者肾病的总患病率。研究结果表明,糖尿病患者中肾病的总患病率为21% (95%,CI: 16-28)。在1型和2型糖尿病患者中,肾病的总患病率分别为46% (95%,CI: 18-77, I²= 98%)和20% (95% CI: 14-27, I²= 98%)。北非、中非、南非和西非的加权患病率分别为47%、31%、33%和11%。结果还显示,合并高血压的糖尿病患者发生肾病的风险是没有高血压的糖尿病患者的3倍多OR:3.46 (95% CI: 2.61-4.59)。结论:当前研究显示糖尿病患者肾病患病率与高血压有显著相关性。北非较高的患病率可能是由于西方文化对饮食消费的影响。系统综述注册:https://www.crd.york.ac.uk/prospero/,标识符CRD42024587467。
{"title":"Prevalence of nephropathy among patients with diabetes mellitus in Africa: a systematic review and meta-analysis.","authors":"Grace I Adebayo-Gege, Peter Ifeoluwa Adegbola, Lawrence Dayo Adedayo, Adegboyega Moses Oyefabi, Ifeoluwa Temitayo Oyeyemi, Odeniran Olubukola, Adewale Adegboyega Oke, Oluchukwu Perpetual Okeke, Olunike Rebecca Abodunrin, Folahanmi Tomiwa Akinsolu, Olajide Odunayo Sobande","doi":"10.3389/fcdhc.2025.1551088","DOIUrl":"https://doi.org/10.3389/fcdhc.2025.1551088","url":null,"abstract":"<p><strong>Background: </strong>Diabetic nephropathy (DN) is one of the most frequent microvascular consequences of diabetes, accounting for a significant portion of morbidity and mortality in diabetic patients in Africa. This study aims to report on the prevalence of nephropathy among patients with diabetes mellitus patients in Africa and the risk factors.</p><p><strong>Methods: </strong>This systematic review was reported using Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) standards, and the protocol was pre-registered in PROSPERO with the registration number CRD42024587467. The search was conducted across databases such as PubMed, Google Scholar, CINAHL and Scopus to retrieve studies published between January 2000 and August 2024. All statistical analyses were conducted using R software (version 4.4.2). The pooled prevalence of nephropathy in patients with diabetes was calculated with a 95% confidence interval (CI).</p><p><strong>Results: </strong>Thirty-four (34) articles met the inclusion criteria. Only 28 studies were incorporated into the meta-analysis to determine the pooled prevalence of nephropathy among diabetes patients. The findings indicated a pooled prevalence of 21% (95%, CI: 16-28) of nephropathy among diabetes patients. Among type 1 and type 2 diabetes patients, the pooled prevalence of nephropathy is 46% (95%, CI: 18-77, I² = 98%) and 20% (95% CI: 14-27, I² = 98%), respectively. Weighted prevalence of 47%, 31%, 33% and 11% were reported in North Africa, Central Africa, South Africa and West Africa respectively. The result also showed that diabetes patients with hypertension are more than three times at risk of developing nephropathy compared to those without hypertension OR:3.46 (95% CI: 2.61-4.59).</p><p><strong>Conclusion: </strong>The current study showed the prevalence of nephropathy with a significant association with hypertension among diabetic mellitus patients. Higher prevalence in North Africa is likely due to Western cultural impacts on dietary consumption.</p><p><strong>Systematic review registration: </strong>https://www.crd.york.ac.uk/prospero/, identifier CRD42024587467.</p>","PeriodicalId":73075,"journal":{"name":"Frontiers in clinical diabetes and healthcare","volume":"6 ","pages":"1551088"},"PeriodicalIF":0.0,"publicationDate":"2025-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12061956/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144057599","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Consumer-oriented review of digital diabetes prevention programs: insights from the CDC's diabetes prevention recognition program. 以消费者为导向的数字化糖尿病预防项目综述:来自疾病预防控制中心糖尿病预防识别项目的见解。
Pub Date : 2025-04-16 eCollection Date: 2025-01-01 DOI: 10.3389/fcdhc.2025.1562108
Benjamin Lalani, Jalene Shim, Vidhu Vadini, Yllka Valdez, Daniel Zade, Nestoras Mathioudakis

Background: Prediabetes is highly prevalent and significantly increases the risk of type 2 diabetes. While access to proven interventions like the Diabetes Prevention Program (DPP) has historically been limited, digital DPPs (dDPPs) present a promising and scalable option. With the recent growth of dDPP offerings and potential variability across platforms, access to accurate and clear information is crucial for individuals seeking diabetes prevention options. This review provides an overview of the dDPP landscape and characterizes the "direct-to-consumer" information available-or lacking-for patients choosing a dDPP.

Methods: We identified dDPPs through the CDC Diabetes Prevention Recognition Program (DPRP) Registry. Data were extracted from three sources available to consumers: the CDC DPRP Registry, the CDC "Find a Lifestyle Program" Website, and program-specific websites. Extracted data included CDC recognition status, intended audience, available languages, program features (e.g., artificial intelligence, integration with smart devices), website availability and functionality, demonstrations of credibility (e.g., ADA endorsement), clinical performance metrics (e.g., average weight loss), and user experience factors (e.g., satisfaction). Descriptive statistics were used to summarize extracted data.

Results: A total of 97 dDPPs were included in the review, with most in the early stages of CDC recognition. Only 35% of dDPPs listed in the CDC registry had functional websites, though additional websites were identified through manual searches. Program-specific features included AI-driven health recommendations, device integration (e.g., digital scales and activity trackers), nutrition tracking tools, and telehealth platforms. Nearly half of the dDPPs reported clinical performance metrics such as weight loss and A1C outcomes. User experience details were often presented through patient testimonials and satisfaction scores. Notably, many programs required users to provide personal information to access additional information.

Conclusion: We found that available dDPPs vary significantly in their features, designs, and structures, reflecting a diverse and evolving landscape of diabetes prevention options. Concurrently, many dDPPs lack accessible information due to missing or incomplete websites. Centralized sources of information provided by the CDC are also insufficient, with discrepancies and gaps that hinder transparency and consumer decision-making. Addressing these issues through enhanced program visibility and improved centralized databases will be critical to optimizing the reach and impact of dDPPs.

背景:前驱糖尿病非常普遍,并显著增加2型糖尿病的风险。虽然像糖尿病预防计划(DPP)这样经过验证的干预措施在历史上一直受到限制,但数字DPP (DPP)提供了一个有前途且可扩展的选择。随着最近dDPP产品的增长和跨平台的潜在变异性,获得准确和清晰的信息对于寻求糖尿病预防选择的个人至关重要。本综述概述了dDPP的概况,并描述了选择dDPP的患者可获得或缺乏的“直接面向消费者”的信息。方法:我们通过美国疾病控制与预防中心糖尿病预防识别计划(DPRP)登记处确定ddpp。数据来自消费者可获得的三个来源:疾病预防控制中心DPRP登记处,疾病预防控制中心“寻找生活方式计划”网站和计划特定网站。提取的数据包括CDC识别状态、目标受众、可用语言、程序功能(如人工智能、与智能设备的集成)、网站可用性和功能、可信度证明(如ADA认可)、临床表现指标(如平均体重减轻)和用户体验因素(如满意度)。采用描述性统计对提取的数据进行汇总。结果:共纳入97个ddpp,大多数处于CDC识别的早期阶段。疾控中心注册表中列出的ddpp中只有35%拥有功能性网站,尽管通过人工搜索确定了其他网站。具体的方案功能包括人工智能驱动的健康建议、设备集成(例如,数字秤和活动跟踪器)、营养跟踪工具和远程医疗平台。近一半的ddpp报告了临床表现指标,如体重减轻和A1C结果。用户体验细节通常通过患者推荐和满意度评分来呈现。值得注意的是,许多程序需要用户提供个人信息才能访问其他信息。结论:我们发现现有的ddpp在其特征、设计和结构上存在显著差异,反映了糖尿病预防选择的多样性和不断发展的前景。同时,由于网站缺失或不完整,许多ddpp缺乏可访问的信息。疾病预防控制中心提供的集中信息来源也不够充分,存在差异和差距,妨碍了透明度和消费者决策。通过增强项目可见性和改进集中式数据库来解决这些问题,对于优化ddpp的覆盖范围和影响至关重要。
{"title":"Consumer-oriented review of digital diabetes prevention programs: insights from the CDC's diabetes prevention recognition program.","authors":"Benjamin Lalani, Jalene Shim, Vidhu Vadini, Yllka Valdez, Daniel Zade, Nestoras Mathioudakis","doi":"10.3389/fcdhc.2025.1562108","DOIUrl":"https://doi.org/10.3389/fcdhc.2025.1562108","url":null,"abstract":"<p><strong>Background: </strong>Prediabetes is highly prevalent and significantly increases the risk of type 2 diabetes. While access to proven interventions like the Diabetes Prevention Program (DPP) has historically been limited, digital DPPs (dDPPs) present a promising and scalable option. With the recent growth of dDPP offerings and potential variability across platforms, access to accurate and clear information is crucial for individuals seeking diabetes prevention options. This review provides an overview of the dDPP landscape and characterizes the \"direct-to-consumer\" information available-or lacking-for patients choosing a dDPP.</p><p><strong>Methods: </strong>We identified dDPPs through the CDC Diabetes Prevention Recognition Program (DPRP) Registry. Data were extracted from three sources available to consumers: the CDC DPRP Registry, the CDC \"Find a Lifestyle Program\" Website, and program-specific websites. Extracted data included CDC recognition status, intended audience, available languages, program features (e.g., artificial intelligence, integration with smart devices), website availability and functionality, demonstrations of credibility (e.g., ADA endorsement), clinical performance metrics (e.g., average weight loss), and user experience factors (e.g., satisfaction). Descriptive statistics were used to summarize extracted data.</p><p><strong>Results: </strong>A total of 97 dDPPs were included in the review, with most in the early stages of CDC recognition. Only 35% of dDPPs listed in the CDC registry had functional websites, though additional websites were identified through manual searches. Program-specific features included AI-driven health recommendations, device integration (e.g., digital scales and activity trackers), nutrition tracking tools, and telehealth platforms. Nearly half of the dDPPs reported clinical performance metrics such as weight loss and A1C outcomes. User experience details were often presented through patient testimonials and satisfaction scores. Notably, many programs required users to provide personal information to access additional information.</p><p><strong>Conclusion: </strong>We found that available dDPPs vary significantly in their features, designs, and structures, reflecting a diverse and evolving landscape of diabetes prevention options. Concurrently, many dDPPs lack accessible information due to missing or incomplete websites. Centralized sources of information provided by the CDC are also insufficient, with discrepancies and gaps that hinder transparency and consumer decision-making. Addressing these issues through enhanced program visibility and improved centralized databases will be critical to optimizing the reach and impact of dDPPs.</p>","PeriodicalId":73075,"journal":{"name":"Frontiers in clinical diabetes and healthcare","volume":"6 ","pages":"1562108"},"PeriodicalIF":0.0,"publicationDate":"2025-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12040819/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144047556","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Design and methods of a multicenter randomized clinical trial of effects of diabetes-educated psychologist on glucose management and diabetes distress. 糖尿病教育心理学家对血糖管理和糖尿病困扰影响的多中心随机临床试验的设计和方法
Pub Date : 2025-04-16 eCollection Date: 2025-01-01 DOI: 10.3389/fcdhc.2025.1549234
Johanna Zeijlemaker, Therese Anderbro, Sofia Sterner Isaksson, Marcus Lind

Introduction: Many people with type 1 diabetes struggle to manage their glucose levels and experience stress related to the behavioral demands of the disease. The aim of this study is to investigate whether treatment with a diabetes-educated psychologist can improve glucose levels and decrease diabetes distress.

Materials and methods: Individuals with HbA1c >62 mmol/mol (7.8%) were randomized to either psychological treatment or control group. The study duration for each participant was 52 weeks. Patients who received treatment met with a diabetes-educated psychologist a minimum of seven times. In total 6 outpatient diabetes units and 10 psychologists participated. Cognitive behavioral therapy was primarily the treatment of choice. Both groups met with a diabetes nurse and/or physician at the start of the study and at 3, 6, and 12 months. HbA1c, blood pressure, and weight were measured at scheduled visits. Diabetes distress, quality of life, hypoglycemia confidence, and treatment satisfaction were evaluated using questionnaires. The primary endpoint is the difference in HbA1c from baseline to week 52. Secondary endpoints are changes in diabetes distress and quality of life from baseline to week 52, as well as treatment satisfaction at 52 weeks.

Discussion: This study seeks to improve knowledge about how to support patients who struggle to manage their diabetes. If the results of this study show that psychological treatment has an effect on HbA1c or on diabetes distress, it could indicate that psychologists should become more involved in diabetes care teams. Clinical trial registration: ClinicalTrials.gov ID NCT03753997.

导言:许多1型糖尿病患者努力控制血糖水平,并经历与疾病行为要求相关的压力。这项研究的目的是调查接受过糖尿病教育的心理学家的治疗是否能改善血糖水平,减少糖尿病的痛苦。材料与方法:将糖化血红蛋白(HbA1c)≤62 mmol/mol(7.8%)的个体随机分为心理治疗组和对照组。每位参与者的研究时间为52周。接受治疗的患者至少与糖尿病教育的心理学家会面七次。共有6个糖尿病门诊单位和10名心理医生参与。认知行为疗法是主要的治疗选择。两组患者在研究开始时、3个月、6个月和12个月时均会见糖尿病护士和/或医生。在预定的访问中测量HbA1c、血压和体重。采用问卷调查的方式对糖尿病患者的痛苦程度、生活质量、对低血糖的信心和治疗满意度进行评估。主要终点是HbA1c从基线到第52周的差异。次要终点是糖尿病痛苦和生活质量从基线到52周的变化,以及52周时的治疗满意度。讨论:本研究旨在提高对如何支持那些努力控制糖尿病的患者的认识。如果这项研究的结果表明心理治疗对HbA1c或糖尿病痛苦有影响,这可能表明心理学家应该更多地参与糖尿病护理团队。临床试验注册:ClinicalTrials.gov ID NCT03753997。
{"title":"Design and methods of a multicenter randomized clinical trial of effects of diabetes-educated psychologist on glucose management and diabetes distress.","authors":"Johanna Zeijlemaker, Therese Anderbro, Sofia Sterner Isaksson, Marcus Lind","doi":"10.3389/fcdhc.2025.1549234","DOIUrl":"https://doi.org/10.3389/fcdhc.2025.1549234","url":null,"abstract":"<p><strong>Introduction: </strong>Many people with type 1 diabetes struggle to manage their glucose levels and experience stress related to the behavioral demands of the disease. The aim of this study is to investigate whether treatment with a diabetes-educated psychologist can improve glucose levels and decrease diabetes distress.</p><p><strong>Materials and methods: </strong>Individuals with HbA1c >62 mmol/mol (7.8%) were randomized to either psychological treatment or control group. The study duration for each participant was 52 weeks. Patients who received treatment met with a diabetes-educated psychologist a minimum of seven times. In total 6 outpatient diabetes units and 10 psychologists participated. Cognitive behavioral therapy was primarily the treatment of choice. Both groups met with a diabetes nurse and/or physician at the start of the study and at 3, 6, and 12 months. HbA1c, blood pressure, and weight were measured at scheduled visits. Diabetes distress, quality of life, hypoglycemia confidence, and treatment satisfaction were evaluated using questionnaires. The primary endpoint is the difference in HbA1c from baseline to week 52. Secondary endpoints are changes in diabetes distress and quality of life from baseline to week 52, as well as treatment satisfaction at 52 weeks.</p><p><strong>Discussion: </strong>This study seeks to improve knowledge about how to support patients who struggle to manage their diabetes. If the results of this study show that psychological treatment has an effect on HbA1c or on diabetes distress, it could indicate that psychologists should become more involved in diabetes care teams. Clinical trial registration: ClinicalTrials.gov ID NCT03753997.</p>","PeriodicalId":73075,"journal":{"name":"Frontiers in clinical diabetes and healthcare","volume":"6 ","pages":"1549234"},"PeriodicalIF":0.0,"publicationDate":"2025-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12040910/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144059949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Perspectives of type 2 diabetes mellitus management in Algeria: a comprehensive expert review. 阿尔及利亚2型糖尿病管理的观点:一项全面的专家综述。
Pub Date : 2025-04-15 eCollection Date: 2025-01-01 DOI: 10.3389/fcdhc.2025.1495849
Mohamed Belhadj, Rachid Malek, Houssem Baghous, Mourad Boukheloua, Zakia Arbouche, Nassim Nouri, Mohammed El Amine Amani, Fethia Sersoub, Mohamed Amine Haireche

Background: The health and economic impacts of type 2 diabetes mellitus (T2DM) remain substantial, notably in developing countries.

Objectives: To provide an in-depth assessment of the T2DM situation in Algeria to understand its multifaceted burden and identify priority areas of intervention.

Methods: A systematic literature search was conducted on all published articles about T2DM in Algeria over the past 30 years, including original research, reviews, and case series. The extracted data were thoroughly analyzed and synthesized by a committee of diabetes experts.

Results: Algerian epidemiological data point towards a constant rise of T2DM prevalence, roughly from 8.9% in 2003 to 14.4% in 2016-2017. The mean onset is around 41 years with women experiencing a greater burden at younger age. Low socioeconomic status, limited education, and lack of health insurance exacerbate T2DM risk and health inequities. Lifestyle and metabolic risk factors are prevalent. Despite advancements in glycemic control, prescribing practices lack standardization, with suboptimal use of antidiabetic drugs and absence of novel drugs in the market. Health and economic burdens are dominated by complications, highlighting inadequate primary and tertiary prevention strategies.

Conclusion: Notwithstanding the increasing burden of T2DM in Algeria, the healthcare strategies and therapeutic outcomes remain suboptimal. This underscores the necessity for a comprehensive strategy including enhanced prevention, access to novel treatments, standardized practices, along with a patient-centered approach.

背景:2型糖尿病(T2DM)对健康和经济的影响仍然很大,特别是在发展中国家。目的:对阿尔及利亚的2型糖尿病状况进行深入评估,以了解其多方面的负担,并确定优先干预领域。方法:系统检索阿尔及利亚过去30年来发表的关于2型糖尿病的所有文章,包括原始研究、综述和病例系列。提取的数据由一个糖尿病专家委员会进行了彻底的分析和综合。结果:阿尔及利亚流行病学数据显示,2型糖尿病患病率持续上升,大致从2003年的8.9%上升到2016-2017年的14.4%。平均发病年龄在41岁左右,女性在年轻时负担更重。低社会经济地位、有限的教育和缺乏健康保险加剧了2型糖尿病风险和健康不公平。生活方式和代谢风险因素普遍存在。尽管在血糖控制方面取得了进步,但处方实践缺乏标准化,降糖药的使用不理想,市场上缺乏新药。并发症主要是健康和经济负担,突出表明初级和三级预防战略不足。结论:尽管阿尔及利亚的2型糖尿病负担不断增加,但医疗保健策略和治疗结果仍然不理想。这突出表明有必要制定一项综合战略,包括加强预防、获得新的治疗方法、标准化做法以及以患者为中心的方法。
{"title":"Perspectives of type 2 diabetes mellitus management in Algeria: a comprehensive expert review.","authors":"Mohamed Belhadj, Rachid Malek, Houssem Baghous, Mourad Boukheloua, Zakia Arbouche, Nassim Nouri, Mohammed El Amine Amani, Fethia Sersoub, Mohamed Amine Haireche","doi":"10.3389/fcdhc.2025.1495849","DOIUrl":"https://doi.org/10.3389/fcdhc.2025.1495849","url":null,"abstract":"<p><strong>Background: </strong>The health and economic impacts of type 2 diabetes mellitus (T2DM) remain substantial, notably in developing countries.</p><p><strong>Objectives: </strong>To provide an in-depth assessment of the T2DM situation in Algeria to understand its multifaceted burden and identify priority areas of intervention.</p><p><strong>Methods: </strong>A systematic literature search was conducted on all published articles about T2DM in Algeria over the past 30 years, including original research, reviews, and case series. The extracted data were thoroughly analyzed and synthesized by a committee of diabetes experts.</p><p><strong>Results: </strong>Algerian epidemiological data point towards a constant rise of T2DM prevalence, roughly from 8.9% in 2003 to 14.4% in 2016-2017. The mean onset is around 41 years with women experiencing a greater burden at younger age. Low socioeconomic status, limited education, and lack of health insurance exacerbate T2DM risk and health inequities. Lifestyle and metabolic risk factors are prevalent. Despite advancements in glycemic control, prescribing practices lack standardization, with suboptimal use of antidiabetic drugs and absence of novel drugs in the market. Health and economic burdens are dominated by complications, highlighting inadequate primary and tertiary prevention strategies.</p><p><strong>Conclusion: </strong>Notwithstanding the increasing burden of T2DM in Algeria, the healthcare strategies and therapeutic outcomes remain suboptimal. This underscores the necessity for a comprehensive strategy including enhanced prevention, access to novel treatments, standardized practices, along with a patient-centered approach.</p>","PeriodicalId":73075,"journal":{"name":"Frontiers in clinical diabetes and healthcare","volume":"6 ","pages":"1495849"},"PeriodicalIF":0.0,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12038694/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144063406","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prevalence of in-hospital mortality among adult patients with diabetic ketoacidosis in Ethiopia: a systematic review and meta-analysis of observational studies. 埃塞俄比亚成年糖尿病酮症酸中毒患者的住院死亡率:观察性研究的系统回顾和荟萃分析
Pub Date : 2025-04-08 eCollection Date: 2025-01-01 DOI: 10.3389/fcdhc.2025.1501167
Zenaw Debasu Addisu, Desalegn Getnet Demsie, Dessale Abate Beyene, Chernet Tafere

Background: Diabetic ketoacidosis (DKA) is one of the most common life-threatening acute metabolic complications of diabetes, typically associated with disability, mortality, and significant health costs for all societies. In Ethiopia, available studies on in-hospital mortality rates of people living with DKA have shown high variability. Therefore, this systematic review and meta-analysis aims to summarize and provide quantitative estimates of the prevalence of in-hospital mortality among adult people living with DKA treated in Ethiopian hospitals.

Methodology: A systematic literature search was conducted using MEDLINE, Embase, Google Scholar, Web of Science, and Africa-specific databases. Data were extracted in a structured format prepared using Microsoft Excel. The extracted data were exported to R software Version 4.3.0 for analysis. The I2 test was used to check the heterogeneity between primary studies with a corresponding 95% confidence interval (CI). Based on the test result, a random-effects meta-analysis model was used to estimate Der Simonian and Laird's pooled effect on in-hospital mortality.

Result: The review included a total of 5 primary studies. The pooled prevalence of in-hospital mortality among people living with DKA who received treatment in Ethiopia hospitals was found to be 7% (95% CI: 1-12). Most of the included studies reported that nonadherence to insulin treatment followed by infection was the most common triggering factor for the development of DKA.

Conclusion: The prevalence of in-hospital mortality among people living with DKA was found to be 7%. This figure is unacceptably high compared to other published reports. Nonadherence to insulin treatment or antidiabetic medication and infection were identified as precipitating factors for developing DKA. Therefore, measures must be taken to improve medication adherence and decrease in-hospital mortality by providing ongoing health education on medication usage, effective in-hospital management of hyperglycemia, and increased access to high-quality care.

Systematic review registration: https://www.crd.york.ac.uk/prospero/, identifier CRD42023432594.

背景:糖尿病酮症酸中毒(DKA)是糖尿病最常见的危及生命的急性代谢并发症之一,通常与残疾、死亡率和所有社会的重大卫生成本相关。在埃塞俄比亚,现有的关于DKA患者住院死亡率的研究表明差异很大。因此,本系统综述和荟萃分析旨在总结并提供埃塞俄比亚医院治疗的DKA成人住院死亡率流行率的定量估计。方法:使用MEDLINE、Embase、谷歌Scholar、Web of Science和非洲特定数据库进行系统的文献检索。数据提取采用Microsoft Excel编制的结构化格式。提取的数据导出到R软件4.3.0进行分析。I2检验用于检查主要研究之间的异质性,并有相应的95%置信区间(CI)。根据检验结果,采用随机效应荟萃分析模型估计Der Simonian和Laird的合并效应对住院死亡率的影响。结果:本综述共纳入5项初步研究。在埃塞俄比亚医院接受治疗的DKA患者住院死亡率的总流行率为7% (95% CI: 1-12)。大多数纳入的研究报告,不坚持胰岛素治疗后感染是DKA发展的最常见触发因素。结论:DKA患者住院死亡率为7%。与其他已发表的报告相比,这一数字高得令人无法接受。不坚持胰岛素治疗或抗糖尿病药物和感染被确定为诱发DKA的因素。因此,必须采取措施,通过提供持续的药物使用健康教育,有效的高血糖住院管理,增加获得高质量护理的机会,提高药物依从性,降低院内死亡率。系统综述注册:https://www.crd.york.ac.uk/prospero/,标识符CRD42023432594。
{"title":"Prevalence of in-hospital mortality among adult patients with diabetic ketoacidosis in Ethiopia: a systematic review and meta-analysis of observational studies.","authors":"Zenaw Debasu Addisu, Desalegn Getnet Demsie, Dessale Abate Beyene, Chernet Tafere","doi":"10.3389/fcdhc.2025.1501167","DOIUrl":"https://doi.org/10.3389/fcdhc.2025.1501167","url":null,"abstract":"<p><strong>Background: </strong>Diabetic ketoacidosis (DKA) is one of the most common life-threatening acute metabolic complications of diabetes, typically associated with disability, mortality, and significant health costs for all societies. In Ethiopia, available studies on in-hospital mortality rates of people living with DKA have shown high variability. Therefore, this systematic review and meta-analysis aims to summarize and provide quantitative estimates of the prevalence of in-hospital mortality among adult people living with DKA treated in Ethiopian hospitals.</p><p><strong>Methodology: </strong>A systematic literature search was conducted using MEDLINE, Embase, Google Scholar, Web of Science, and Africa-specific databases. Data were extracted in a structured format prepared using Microsoft Excel. The extracted data were exported to R software Version 4.3.0 for analysis. The I<sup>2</sup> test was used to check the heterogeneity between primary studies with a corresponding 95% confidence interval (CI). Based on the test result, a random-effects meta-analysis model was used to estimate Der Simonian and Laird's pooled effect on in-hospital mortality.</p><p><strong>Result: </strong>The review included a total of 5 primary studies. The pooled prevalence of in-hospital mortality among people living with DKA who received treatment in Ethiopia hospitals was found to be 7% (95% CI: 1-12). Most of the included studies reported that nonadherence to insulin treatment followed by infection was the most common triggering factor for the development of DKA.</p><p><strong>Conclusion: </strong>The prevalence of in-hospital mortality among people living with DKA was found to be 7%. This figure is unacceptably high compared to other published reports. Nonadherence to insulin treatment or antidiabetic medication and infection were identified as precipitating factors for developing DKA. Therefore, measures must be taken to improve medication adherence and decrease in-hospital mortality by providing ongoing health education on medication usage, effective in-hospital management of hyperglycemia, and increased access to high-quality care.</p><p><strong>Systematic review registration: </strong>https://www.crd.york.ac.uk/prospero/, identifier CRD42023432594.</p>","PeriodicalId":73075,"journal":{"name":"Frontiers in clinical diabetes and healthcare","volume":"6 ","pages":"1501167"},"PeriodicalIF":0.0,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12011865/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144055338","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Using blood biomarkers and ophthalmological indicators of optical coherence tomography and angiography for the diagnosis of fundus lesions in patients with diabetes mellitus. 应用血液生物标志物和光学相干断层扫描及血管造影眼科指标诊断糖尿病眼底病变。
Pub Date : 2025-04-08 eCollection Date: 2025-01-01 DOI: 10.3389/fcdhc.2025.1499344
Fanny Huang, Miaomiao Yu, Laura Huang, Ruikang K Wang, Theodore Leng, Sophia Y Wang, Yaping Joyce Liao

Purpose: To assess long-term ophthalmic and clinical blood test changes in patients with different severities of diabetic retinopathy (DR).

Methods: We performed a longitudinal case-control study of 130 patients with diabetes mellitus (DM) and 67 controls, including visual acuities from 2,201 eye clinic visits and 44,833 blood tests. We also analyzed optic disc and macular structure and vasculature using optical coherence tomography (OCT) and angiography (OCTA).

Results: Ninety-one percent of eyes in diabetic patients had stable visual acuity (better than 20/40) over 7 years. Cluster analysis revealed most prominent blood test changes in the DM included elevated glucose and hemoglobin A1c and evidence of nephropathy. Optic disc OCTA was most correlated with OCT in the superior and inferior quadrants. Notably, peripapillary and macular OCTA measurements revealed evidence of microvascular drop out even in those with DR grade 0.

Conclusions: Majority of patients with DM monitored by physicians maintained good visual acuity over years. Ophthalmic imaging revealed evidence of early vascular changes even in patients without evidence of DR on clinical exam and color fundus imaging. In addition to ophthalmic functional and structural assessments, clinical blood tests for renal function are also important early biomarkers of end organ damage in DM.

目的:探讨不同严重程度糖尿病视网膜病变(DR)患者的长期眼科及临床血液检查变化。方法:我们对130例糖尿病患者和67例对照者进行了纵向病例对照研究,包括2201例眼科就诊的视力和44,833例血液检查。我们还使用光学相干断层扫描(OCT)和血管造影(OCTA)分析视盘和黄斑结构和血管。结果:糖尿病患者视力稳定(≥20/40)7年,占91%。聚类分析显示,糖尿病最显著的血液检查变化包括血糖和血红蛋白A1c升高以及肾病的证据。视盘OCTA与OCT在上、下象限的相关性最强。值得注意的是,即使在DR 0级患者中,乳头周围和黄斑的OCTA测量也显示微血管脱落的证据。结论:大多数糖尿病患者在医生的监测下保持了良好的视力。眼科影像学显示,即使在临床检查和眼底彩色成像中没有DR证据的患者,也有早期血管改变的证据。除了眼科功能和结构评估外,肾脏功能的临床血液检查也是糖尿病终末器官损伤的重要早期生物标志物。
{"title":"Using blood biomarkers and ophthalmological indicators of optical coherence tomography and angiography for the diagnosis of fundus lesions in patients with diabetes mellitus.","authors":"Fanny Huang, Miaomiao Yu, Laura Huang, Ruikang K Wang, Theodore Leng, Sophia Y Wang, Yaping Joyce Liao","doi":"10.3389/fcdhc.2025.1499344","DOIUrl":"https://doi.org/10.3389/fcdhc.2025.1499344","url":null,"abstract":"<p><strong>Purpose: </strong>To assess long-term ophthalmic and clinical blood test changes in patients with different severities of diabetic retinopathy (DR).</p><p><strong>Methods: </strong>We performed a longitudinal case-control study of 130 patients with diabetes mellitus (DM) and 67 controls, including visual acuities from 2,201 eye clinic visits and 44,833 blood tests. We also analyzed optic disc and macular structure and vasculature using optical coherence tomography (OCT) and angiography (OCTA).</p><p><strong>Results: </strong>Ninety-one percent of eyes in diabetic patients had stable visual acuity (better than 20/40) over 7 years. Cluster analysis revealed most prominent blood test changes in the DM included elevated glucose and hemoglobin A1c and evidence of nephropathy. Optic disc OCTA was most correlated with OCT in the superior and inferior quadrants. Notably, peripapillary and macular OCTA measurements revealed evidence of microvascular drop out even in those with DR grade 0.</p><p><strong>Conclusions: </strong>Majority of patients with DM monitored by physicians maintained good visual acuity over years. Ophthalmic imaging revealed evidence of early vascular changes even in patients without evidence of DR on clinical exam and color fundus imaging. In addition to ophthalmic functional and structural assessments, clinical blood tests for renal function are also important early biomarkers of end organ damage in DM.</p>","PeriodicalId":73075,"journal":{"name":"Frontiers in clinical diabetes and healthcare","volume":"6 ","pages":"1499344"},"PeriodicalIF":0.0,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12011831/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144047611","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
System accuracy evaluation of the new blood glucose monitoring meter "GLUCOCARD S onyx" beyond ISO 15197:2013/EN ISO 15197:2015 requirements and with new patient safety features. 新型血糖监测仪“GLUCOCARD S onyx”的系统精度评估超出了ISO 15197:2013/EN ISO 15197:2015要求,并具有新的患者安全功能。
Pub Date : 2025-04-03 eCollection Date: 2025-01-01 DOI: 10.3389/fcdhc.2025.1465732
Daisuke Azuma, Hisashi Okuda, Beate Saeger

Introduction: Blood glucose monitoring meters (BGM) have not become redundant yet. The accuracy and precision of "GLUCOCARD S onyx," a new BGM with Bluetooth function, has been evaluated and proven to exceed the actual ISO 15197:2013/EN ISO 15197:2015 guidelines besides offering features for better patient safety and telemedicine.

Methods: 100 finger-prick whole blood samples from subjects with diabetes and 32 without diabetes were collected and measured with GLUCOCARD S onyx. Plasma blood glucose levels were measured using YSI2300 STAT PLUS as reference analyzer for comparison. The evaluation followed ISO 15197:2013, section 6.3 accuracy criteria. Furthermore, the MARD factor was calculated for the overall clinical important range (with n=132 samples).

Results: The performance of GLUCOCARD S onyx was evaluated according to ISO 15197:2013, revealing that 99.7% (598/600) of the results fell within ±15% or ±0.8 mmol/L (± 15 mg/dL) of difference over the total clinically relevant glucose range compared to the YSI2300 STAT PLUS. 100% (600/600) of the measurement results over the total range fell within Clark Error Grid Zone A. An overall mean absolute relative difference (MARD) factor of 4.15% was obtained; 5.05% for glucose <5.6 mmol/L (<100 mg/dL), and 3.65% for glucose ≥5.6 mmol/L (≥100 mg/dL).

Discussion: GLUCOCARD S onyx shows clinically satisfactory accuracy and reliability, even exceeding the ISO 15197:2013 criteria, for hypoglycemic cases with glucose critically low as <3.9 mmol/L (<70 mg/dL) and hyperglycemic cases with glucose ≥10.0 mmol/L (≥180 mg/dL). Healthcare organizations as well as manufacturers are aiming to offer new BGM systems that go beyond the ISO criteria and offer systems that can be consulted instead or besides CGM (Continuous Glucose Monitoring) in case of e.g. severe hypo- and/or hyperglycemic episodes. A MARD factor of 4.15% revealed an excellent system accuracy over the total clinically relevant glucose range. With additional user-friendly features, this BGM can be seen as a useful tool for efficient diabetes therapy, especially in the event of severe blood glucose fluctuations.

简介:血糖监测仪(BGM)还没有成为多余的设备。“GLUCOCARD S onyx”是一款具有蓝牙功能的新型BGM,其准确性和精密度已经过评估并证明超过了实际的ISO 15197:2013/EN ISO 15197:2015指南,此外还提供了更好的患者安全和远程医疗功能。方法:采集100例糖尿病患者和32例非糖尿病患者的指刺全血,应用GLUCOCARD S - onyx进行测定。采用YSI2300 STAT PLUS作为参考分析仪测定血浆血糖水平进行比较。评估遵循ISO 15197:2013, 6.3节精度标准。此外,计算了总体临床重要范围(n=132个样本)的MARD因子。结果:根据ISO 15197:2013对GLUCOCARD S onyx的性能进行了评估,结果显示,与YSI2300 STAT PLUS相比,99.7%(598/600)的结果在临床相关血糖总范围内的差异在±15%或±0.8 mmol/L(±15 mg/dL)。总范围内100%(600/600)的测量结果落在Clark Error Grid Zone a内,总体平均绝对相对差(MARD)因子为4.15%;讨论:GLUCOCARD S onyx在临床表现出令人满意的准确性和可靠性,甚至超过了ISO 15197:2013标准,用于血糖极低的低血糖病例
{"title":"System accuracy evaluation of the new blood glucose monitoring meter \"GLUCOCARD S onyx\" beyond ISO 15197:2013/EN ISO 15197:2015 requirements and with new patient safety features.","authors":"Daisuke Azuma, Hisashi Okuda, Beate Saeger","doi":"10.3389/fcdhc.2025.1465732","DOIUrl":"https://doi.org/10.3389/fcdhc.2025.1465732","url":null,"abstract":"<p><strong>Introduction: </strong>Blood glucose monitoring meters (BGM) have not become redundant yet. The accuracy and precision of \"GLUCOCARD S onyx,\" a new BGM with Bluetooth function, has been evaluated and proven to exceed the actual ISO 15197:2013/EN ISO 15197:2015 guidelines besides offering features for better patient safety and telemedicine.</p><p><strong>Methods: </strong>100 finger-prick whole blood samples from subjects with diabetes and 32 without diabetes were collected and measured with GLUCOCARD S onyx. Plasma blood glucose levels were measured using YSI2300 STAT PLUS as reference analyzer for comparison. The evaluation followed ISO 15197:2013, section 6.3 accuracy criteria. Furthermore, the MARD factor was calculated for the overall clinical important range (with n=132 samples).</p><p><strong>Results: </strong>The performance of GLUCOCARD S onyx was evaluated according to ISO 15197:2013, revealing that 99.7% (598/600) of the results fell within ±15% or ±0.8 mmol/L (± 15 mg/dL) of difference over the total clinically relevant glucose range compared to the YSI2300 STAT PLUS. 100% (600/600) of the measurement results over the total range fell within Clark Error Grid Zone A. An overall mean absolute relative difference (MARD) factor of 4.15% was obtained; 5.05% for glucose <5.6 mmol/L (<100 mg/dL), and 3.65% for glucose ≥5.6 mmol/L (≥100 mg/dL).</p><p><strong>Discussion: </strong>GLUCOCARD S onyx shows clinically satisfactory accuracy and reliability, even exceeding the ISO 15197:2013 criteria, for hypoglycemic cases with glucose critically low as <3.9 mmol/L (<70 mg/dL) and hyperglycemic cases with glucose ≥10.0 mmol/L (≥180 mg/dL). Healthcare organizations as well as manufacturers are aiming to offer new BGM systems that go beyond the ISO criteria and offer systems that can be consulted instead or besides CGM (Continuous Glucose Monitoring) in case of e.g. severe hypo- and/or hyperglycemic episodes. A MARD factor of 4.15% revealed an excellent system accuracy over the total clinically relevant glucose range. With additional user-friendly features, this BGM can be seen as a useful tool for efficient diabetes therapy, especially in the event of severe blood glucose fluctuations.</p>","PeriodicalId":73075,"journal":{"name":"Frontiers in clinical diabetes and healthcare","volume":"6 ","pages":"1465732"},"PeriodicalIF":0.0,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12003385/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144052092","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Gestational diabetes mellitus - more than the eye can see - a warning sign for future maternal health with transgenerational impact. 妊娠期糖尿病——超出肉眼所能看到的范围——是一个对未来孕产妇健康具有跨代影响的警告信号。
Pub Date : 2025-04-01 eCollection Date: 2025-01-01 DOI: 10.3389/fcdhc.2025.1527076
Manal Massalha, Rula Iskander, Haya Hassan, Etty Spiegel, Offer Erez, Zohar Nachum

Gestational diabetes mellitus (GDM) is regarded by many as maternal maladaptation to physiological insulin resistance during the second half of pregnancy. However, recent evidence indicates that alterations in carbohydrate metabolism can already be detected in early pregnancy. This observation, the increasing prevalence of GDM, and the significant short and long-term implications for the mother and offspring call for reevaluation of the conceptual paradigm of GDM as a syndrome. This review will present evidence for the syndromic nature of GDM and the controversies regarding screening, diagnosis, management, and treatment.

妊娠期糖尿病(GDM)被许多人认为是孕妇在妊娠后半期对生理性胰岛素抵抗的不适应。然而,最近的证据表明,在怀孕早期已经可以检测到碳水化合物代谢的变化。这一观察结果,GDM患病率的增加,以及对母亲和后代的重大短期和长期影响,要求重新评估GDM作为一种综合征的概念范式。本综述将为GDM的综合征性质和关于筛查、诊断、管理和治疗的争议提供证据。
{"title":"Gestational diabetes mellitus - more than the eye can see - a warning sign for future maternal health with transgenerational impact.","authors":"Manal Massalha, Rula Iskander, Haya Hassan, Etty Spiegel, Offer Erez, Zohar Nachum","doi":"10.3389/fcdhc.2025.1527076","DOIUrl":"https://doi.org/10.3389/fcdhc.2025.1527076","url":null,"abstract":"<p><p>Gestational diabetes mellitus (GDM) is regarded by many as maternal maladaptation to physiological insulin resistance during the second half of pregnancy. However, recent evidence indicates that alterations in carbohydrate metabolism can already be detected in early pregnancy. This observation, the increasing prevalence of GDM, and the significant short and long-term implications for the mother and offspring call for reevaluation of the conceptual paradigm of GDM as a syndrome. This review will present evidence for the syndromic nature of GDM and the controversies regarding screening, diagnosis, management, and treatment.</p>","PeriodicalId":73075,"journal":{"name":"Frontiers in clinical diabetes and healthcare","volume":"6 ","pages":"1527076"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11997571/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144028379","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Frontiers in clinical diabetes and healthcare
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1